Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00079)
Name |
Thromboembolic stroke
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 8B20
|
Full List of Target(s) of This Ferroptosis-centered Disease
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Driver/Suppressor | ||||
Responsed Disease | Thromboembolic stroke [ICD-11: 8B20] | ||||
Responsed Drug | ADA-409-052 | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | BV-2 cells | Normal | Mus musculus | CVCL_0182 | |
Neuro-2a cells | Neuroblastoma | Mus musculus | CVCL_0470 | ||
RAW 264.7 cells | Leukemia | Mus musculus | CVCL_0493 | ||
In Vivo Model |
Brain penetration study was carried out by TCG Lifesciences Ltd (Kolkata, India) in male BALB/c mice (6-8 weeks old; 18-20 g, in-house breeding). Mice were housed individually under 12/12 h lightdark cycle with free access to food and water. In two experiments 10 mg/kg or 30 mg/kg of ADA-409-052 (HPLC Purity: 99.7%) dissolved in Tween-80 (0.5%, Merck, Germany) -methylcellulose (Sigma) solution was administered as a single bolus by oral gavage (p.o.). ADA-409-052- or vehicle-administered mice were sacrificed 0.75, 4, and 24 h later (n = 3/group).
Click to Show/Hide
|
||||
Response regulation | ADA-409-052 inhibits tert-Butyl hydroperoxide (TBHP)-induced lipid peroxidation (LP) and protects against ferroptotic cell death triggered by glutathione (GSH) depletion or glutathione peroxidase 4 (GPx4) inhibition in neuronal cell lines. Moreover, ADA-409-052 efficiently reduces infarct volume, edema and expression of pro-inflammatory genes in a mouse model of thromboembolic stroke. In addition, ADA-409-052 reduced the expression of stroke-induced Hmox1. | ||||